Neostem,
Inc. (NBS) is a biopharmaceutical company that focuses on developing
cellular therapies and regenerative medicine for patients with serious
diseases and conditions. The company operates through two segments: a
contract development and manufacturing organization (CDMO) and a
development-stage therapeutics segment.
The CDMO segment
provides services to clients in the cell therapy industry, including
contract manufacturing services and engineering solutions. The
therapeutics segment is focused on developing cellular therapies for
patients with serious medical conditions, such as cancer and
autoimmune disorders.
Neostem's lead product candidate is
NBS20, a proprietary formulation of irinotecan for the treatment of
metastatic colorectal cancer. The company is also developing a range
of other cellular therapies, including immunomodulatory and
regenerative medicines.
Neostem,
Inc. (NBS) is a biopharmaceutical company that focuses on developing
cellular therapies and regenerative medicine for patients with serious
diseases and conditions. The company operates through two segments: a
contract development and manufacturing organization (CDMO) and a
development-stage therapeutics segment.